` U.S. Patent No. 10,335,462
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`APOTEX INC.,
`Petitioner
`
`v.
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2024-00631
`Patent 10,335,462
`______________________
`
`
`
`PATENT OWNER’S MOTION TO SEAL
`
`
`
`
`
`
`
`
`
`
`
`IPR2024-00631
` U.S. Patent No. 10,335,462
`
`
`Introduction
`Pursuant to the default protective order and 37 C.F.R. §§ 42.14, 42.54, and
`
`I.
`
`42.55, Patent Owner Novo Nordisk A/S (“Novo”) hereby moves to seal its Reply
`
`to Petitioner’s Reply to Patent Owner’s Preliminary Response (the “Reply”).
`
`Petitioner Apotex Inc. (“Apotex”) has advised Novo that Apotex does not oppose
`
`this motion to seal.
`
`II. Good Cause Exists to Seal the Reply
`Pursuant to the default protective order (filed by Apotex at Appendix A of
`
`Paper 3) and 37 C.F.R. §§ 42.14, 42.54 and 42.55, Novo moves to seal its Reply
`
`submitted concurrently with this motion.
`
`Based on Apotex’s representations, “good cause” exists to seal the Reply
`
`because it includes material that Apotex has represented is non-public business
`
`information. See Celltrion, Inc. v. Genentech, Inc., IPR2016-01667, Pap.31, 4
`
`(July 23, 2018); Greene’s Energy Grp., LLC v. Oil States Energy Servs., LLC,
`
`IPR2014-00216, Pap.27, 5 (Sept. 23, 2014); 37 C.F.R. § 42.54. Specifically,
`
`portions of the Reply contain information that Apotex has designated confidential
`
`in Apotex’s Third Motion to Seal and Apotex’s Motion to Seal and for Entry of a
`
`Protective Order Pursuant to 37 C.F.R. § 42.54. Petitioner has stated that this
`
`information, if “publicly disclosed[,] would likely cause competitive business harm
`
`to Apotex.” Paper 19 at 2.
`
`1
`
`
`
`
`Novo has filed and served on Apotex an unredacted, nonpublic version of
`
`IPR2024-00631
` U.S. Patent No. 10,335,462
`
`
`the corresponding Reply with this motion. Novo will coordinate with Apotex with
`
`respect to the filing of a redacted version of the Reply once Apotex has the
`
`opportunity to identify any redactions Apotex believes are necessary.
`
`III. Conclusion
`For the foregoing reasons, Novo respectfully requests that the Board grant
`
`Dated: July 15, 2024
`
`this motion to seal.
`
`
`
`
`
`Respectfully submitted by:
`
`/Megan Raymond/
`J. Steven Baughman (Reg. No. 47,414)
`Megan Raymond (Reg. No. 72,997)
`Michael Milea (Reg. No. 71, 863)
`Joshua Reich (Reg. No. 75,338)
`
`Attorneys For Patent Owner
`Novo Nordisk A/S
`
`2
`
`
`
`
`IPR2024-00631
` U.S. Patent No. 10,335,462
`
`
`CERTIFICATE OF PAGE COUNT
`
`The undersigned certifies that the foregoing PATENT OWNER’S MOTION
`
`TO SEAL complies with the 15-page limitation in 37 C.F.R. §42.24(a)(1)(v).
`
`Dated: July 15, 2024
`
`
`
`
`
`Respectfully Submitted,
`
`/Megan Raymond/
`By:
`Megan Raymond (Reg. No. 72,997)
`GROOMBRIDGE, WU, BAUGHMAN &
`STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5878
`megan.raymond@groombridgewu.com
`
`
`1
`
`
`
`
`IPR2024-00631
` U.S. Patent No. 10,335,462
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of PATENT OWNER’S
`
`MOTION TO SEAL has been served in its entirety by causing the
`
`aforementioned document to be electronically mailed to the following attorneys of
`
`record for the Petitioner listed below:
`
`John J. Molenda
`Lawrence Kass
`Kyler Doh
`Michael I. Green
`Semaglutide@Steptoe.com
`
`Dated: July 15, 2024
`
`
`
`
`
`
`
` Respectfully submitted,
`By: /Sayem Osman/
`Sayem Osman
`
`2
`
`
`